Promising new osteoporosis treatment developed

Current FDA-approved pharmaceutical-based osteoporosis treatments, such as bisphosphonate drugs and hormone therapies, do not effectively repair bone that has already been lost. In fact, bisphosphonates have been shown to actually inhibit bone redevelopment. Many of these treatments also have serious side effects, including increasing the risk of heart disease, strokes, and breast cancer.

But the supplement developed by Dr Racquel LeGeros by combining magnesium (Mg), zinc (Zn), and fluoride (F) ions in a calcium-phosphate (CaP) matrix does not have the side effects of the current pharmaceutical-based treatments. Furthermore, a Mg/Zn/F-CaP supplement would be inexpensive to produce and would not require FDA approval. Dr LeGeros’ formulation could be available to market as an over-the-counter supplement, pending patent approval.

In her study, Dr LeGeros investigated the effect in rats of Mg/Zn/F-CaP ion combinations on several bone properties: strength, thickness, quality, and composition of bones. Post-mortem examination of the femurs showed that Mg/Zn/F-CaP supplement substantially improved bone strength and thickness even in rats who had only received low doses of the compound.

More studies will be needed, ultimately using human trials to confirm the results. Dr LeGeros said future research may also focus on using Mg/Zn/F-CaP compounds to repair fractures and periodontal bone defects.